• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Sustained LDL-C Control in High-Risk Group via Remote Lipid Program: Daily Dose

Sustained LDL-C Control in High-Risk Group via Remote Lipid Program: Daily Dose / Image Credit: ©New Africa/AdobeStock
©New Africa/AdobeStock

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

Last week, we reported on findings from a study presented at the American College of Cardiology’s 73rd Annual Scientific Session, held April 6-8, 2024, in Atlanta, Georgia that examined the success of a remotely delivered lipid program in achieving target low-density lipoprotein cholesterol (LDL-C) levels.

The study

Researchers enrolled 8294 individuals in the remote lipid management program that ran from 2018 to 2022. Of the full cohort, 2656 had known ASCVD, 2887 had LDL-C >190mg/dL, 1388 had type 2 diabetes (T2D), and 1363 had a 10-year ASCVD risk of ≥7.5%. The majority (7079) were enrolled in medication management while 1215 opted to receive education only. Target LDL-C levels were established for 6 months and 12 months across 4 ASCVD risk groups (ASCVD, hyperlipidemia, T2D, and primary prevention) and were based on the 2018 American College of Cardiology/American Heart Association Cholesterol Guideline (LDL-C target for ASCVD <70 mg/dL and <100 mg/dL for other groups).

The findings

Of the patients fully completing the program, 75.7% achieved target LDL-C levels at 6 months and 83.1% achieved target levels at 12 months, with similar effects among 4 risk groups (P < .001 for all). Participants who discontinued the program, but remained under usual care, had the lowest rates of achieving target LDL-C levels.

Authors' comment

"The attenuated effect on LDL-C in patients who prematurely discontinued the program highlights the need to improve patient engagement to maximize treatment plans."

Click here for more details.

Related Videos
Naomi Fisher, MD, remote blood pressure monitoring
© 2024 MJH Life Sciences

All rights reserved.